To address known data gaps, this study analyzed patients in a large US administrative claims database who had received surgical therapy and/or medical therapy for newly recognized episodes of acromegaly, in order to assess the prevalence of comorbid conditions, treatment patterns, health resource utilization, and costs.

Compared with patients given medical therapy, those treated with surgical therapy had lower monthly healthcare costs during the 6-month pre-index period, and a higher prevalence of hypertension, sleep apnea, cardiac rhythm problems, and abnormal glucose, and higher costs in the 12-month post-index period.

Future research is needed to assess the incremental economic burden associated with acromegaly and the cost-effectiveness of treatment options that cure the disease or decelerate its progression.